EUVIMEDEUVIMED entdecken
Systematische Übersicht

Variance in IC50 in in vitro / ex vivo antimalarial drug susceptibility assays in laboratories across Africa

Chinedu O Egwu iD, Olusola Ajibaye iD, Eniyou Oriero iD, Ndey Fatou Drammeh, Ignatius C Ndong iD, Fatoumata Bojang, Nora N Nganyewo, Alfred Amambua-Ngwa iD

Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)

DOI: 10.1093/jac/dkag187 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.06.2026. Verfasst von Chinedu O Egwu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Disease Control and Elimination, Atlantic Boulevard,…. Hauptthemen laut MEDLINE: Antimalarials, Inhibitory Concentration 50, Plasmodium falciparum, Malaria. Die Arbeit nennt 92 Literaturangaben. Gefördert von: African Research Excellence Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surveillance of antimalarial drug efficacy is essential for drug policy in the fight against malaria. This includes clinical trials of drug efficacy, molecular marker typing and ex vivo/in vitro drug susceptibility tests such as 50% inhibitory concentration (IC50) assay. The goal of this review was to elaborate on the variance in the IC50 assay across labs in sub-Saharan Africa (sSA) where malaria is endemic. We systematically reviewed 71 articles, published between 2015 and 2025, evaluating IC50 in sSA where only 56 were performed in labs in Western (WA), Central (CA), East (EA) and Southern Africa (SA). The IC50 values of the major antimalarial drugs, including dihydroartemisinin (DHA), lumefantrine (LUM), mefloquine (MFQ), amodiaquine (AMD), chloroquine (CQ), piperaquine (PPQ), artesunate (ATS), artemisinin (ART) and quinine (QN), were reported. An F-test performed on the IC50 values from WA and EA, where ex vivo assays were conducted, revealed a statistically significant variation (P value <0.05) in the IC50 values of some major antimalarials (DHA, CQ, LUM and AMD). The geometric means for DHA, CQ, LUM and AMD in WA versus EA were 2.46 versus 2.21, 83.15 versus 34.34, 10.06 versus 10.47, and 10.63 versus 17.61 nM, respectively. The overall ex vivo IC50 values of CQ were generally below the known resistance thresholds. Differences in drug reconstitution solvents, the range of drug concentrations, period of drug exposure (48 or 72 h), and curve-fitting tools and assay methods were observed. These differences together could account for the variance in IC50 values across sSA. We therefore recommend regional harmonization of the IC50 protocol for antimalarial drug efficacy surveillance and formation of a regional quality assessment network of malaria IC50 labs, as a step towards reliable data sharing and integration into strategic plans for malaria elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsInhibitory Concentration 50Plasmodium falciparumMalariaHumansParasitic Sensitivity TestsAfricaAfrica South of the SaharaLaboratoriesArtemisinins

Substanzen

AntimalarialsArtemisinins

Autor:innen und Institutionen

  • Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Disease Control and Elimination, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
  • Medical Biochemistry Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria.
  • Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research, 6, Edmund Crescent off Murtala Mohammed Way, Yaba, Lagos PMB 2013, Nigeria.

ORCID-Profile: Chinedu O Egwu, Olusola Ajibaye, Eniyou Oriero, Ignatius C Ndong, Alfred Amambua-Ngwa

Förderung

  • African Research Excellence Fund

Zitieren

APA

Egwu, C. O., Ajibaye, O., Oriero, E., Drammeh, N. F., Ndong, I. C., Bojang, F., Nganyewo, N. N., & Amambua-Ngwa, A. (2026). Variance in IC50 in in vitro / ex vivo antimalarial drug susceptibility assays in laboratories across Africa. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag187

Vancouver

Egwu CO, Ajibaye O, Oriero E, Drammeh NF, Ndong IC, Bojang F, et al. Variance in IC50 in in vitro / ex vivo antimalarial drug susceptibility assays in laboratories across Africa. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag187

BibTeX
@article{Egwu2026,
  author = {Egwu, Chinedu O and Ajibaye, Olusola and Oriero, Eniyou and Drammeh, Ndey Fatou and Ndong, Ignatius C and Bojang, Fatoumata and Nganyewo, Nora N and Amambua-Ngwa, Alfred},
  title = {Variance in IC50 in in vitro / ex vivo antimalarial drug susceptibility assays in laboratories across Africa},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {7},
  doi = {10.1093/jac/dkag187}
}
Kostenlos starten →